Exclusive Summary

• A CRISPR/Cas gene editing technology platform with completely independent intellectual property rights, ensuring Freedom to Operate by bypassing complex global patent barriers.
• Offers dual potential in diagnostics and prevention: applicable for early cancer screening (detecting circulating DNA/RNA) and the control of infectious diseases.
• Currently in the preclinical research stage, presenting a prime opportunity for global partners seeking early-stage technology licensing or co-development of next-gen diagnostic tools.

Asset Materials

Contact Us for Full Materials